MyFinsight
Home
Blog
About
Contact
Download
Download image
Depreciation and
amortization
$91,563K
Proceeds from issuance of
common stock
$37,616K
Maturities of marketable
securities
$774,478K
Share-based compensation
expense
$33,051K
Change in fair value of
contingent consideration
$25,419K
Noncash lease expense
$7,980K
Deferred income tax
benefit
$5,206K
Inventory valuation
write-down
$1,926K
Other noncash
adjustments, net
-$1,885K
Realized loss (gains)
from sales of...
-$439K
Net cash provided by
operating activities
$47,331K
Net cash provided by
(used in) financing...
$9,130K
Net cash provided by
(used in) investing...
$4,106K
Canceled cashflow
$120,138K
Canceled cashflow
$28,486K
Canceled cashflow
$770,372K
Total revenues
$718,952K
Net change in cash,
cash equivalents,...
$60,567K
Net earnings (loss)
-$38,550K
Accounts payable and
other liabilities
-$24,566K
Accounts receivable
$22,304K
Prepaid expenses and
other assets
$13,179K
Accrued product returns
and rebates
-$7,608K
Inventories
$7,502K
Payment of contingent
consideration
$4,900K
Amortization of
premium/discount on marketable...
$1,529K
Payment of contingent
consideration
$24,257K
Employee taxes paid
related to net share...
$4,229K
Purchases of marketable
securities
$475,941K
Acquisition of sage, net of
cash acquired
$293,093K
Purchases of property and
equipment
$1,338K
Canceled cashflow
$718,952K
Selling
$209,695K
General and
administrative
$123,987K
Total research and
development expenses
$106,235K
Other segment items
$91,142K
Marketing
$78,956K
Cost of revenues
$74,562K
Acquisition-related expenses
$72,925K
Total external
development program...
$62,167K
Internal
employee-related expenses
$44,068K
Early Stage Program
And Other
$20,926K
SPN817
$15,727K
Qelbree
$11,411K
SPN820
$10,075K
ZURZUVAE
$2,145K
ONAPGO
$1,883K
Back
Back
Cash Flow
source: myfinsight.com
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)